The Evidence Hub

What we're thinking

Tap into perspectives and best practices in real-world evidence from scientific and industry leaders engaged in treatment development, commercialization, and payment innovation.

Insight
February 1, 2019

Welcome to the Evidence Hub

Carolyn Magill
CEO, Aetion

Carolyn Magill
CEO, Aetion

Welcome to the Evidence Hub, an ongoing conversation about perspectives, milestones, and best practices in applying real-world evidence in life sciences and value-based health care. Here is where we share our thinking—and invite your thinking—about one of the most powerful levers we have to fix health care: data.

Read moreRead more
Insight
February 15, 2019

The Epidemiology of Databases Part I: Four principles of working with real-world data

Natalia Petruski-Ivleva, Ph.D., Senior Scientist, Aetion

As FDA launches its formal exploration of the use of real-world evidence in regulatory decision-making, Aetion has joined the industry-wide shared learning process. In a three-part series, we outline our key principles of database epidemiology. Part 1: Four principles of working with real-world data.

Read moreRead more
Q&A
February 8, 2019

Where public health and quantitative science overlap: A conversation with senior scientist Erin Comerford

Where do public health and quantitative science overlap? When Erin Comerford, senior scientist at Aetion, went looking for a discipline in which she could pursue her twin fascinations, she found real-world evidence. We spoke with Erin about how RWE delivers clarity to the complex topic of aging and chronic illness.

Read moreRead more
Q&A
January 31, 2019

Leading Change at Pfizer:
A conversation with Chris Boone

As Pfizer embraces a digital transformation—reimagining business and operating models to embrace the role of all data in decision making and strategy—Chris Boone leads the way as lead for Pfizer's Real-World Data and Analytics Center of Excellence. Recently, he spoke with the Evidence Hub about his mission to ensure that real-world evidence delivers value in the search for innovative medicines.

Read moreRead more
Q&A
January 31, 2019

Framework for FDA’s Real-World Evidence Program:
Sebastian Schneeweiss considers implications for biopharma

In December 2018, FDA unveiled its real-world data strategy for regulatory decision-making in Framework for FDA’s Real-World Evidence Program, marking a new phase in accelerating medical product development and innovation. We spoke with Sebastian Schneeweiss, Sc.D., M.D., to learn the implications of the Framework for biopharma and payers.

Read moreRead more
Insight
January 31, 2019

A Year of Acceleration:
Looking ahead at 2019

Bill Geary

Bill Geary, a co-founder and partner at Flare Capital Partners, a leading health care technology venture capital firm, looks forward at 2019 and predicts a watershed year for health care transformation. From chronic care to real-world data, he says, "those who lead will be rewarded."

Read moreRead more

The Evidence Digest

Subscribe to our newsletter for insights and updates on real-world evidence research and applications.
Thank you, you've been subscribed.
Oops! Something went wrong while submitting the form.
©2018 Aetion, Inc.      Terms of Use      Privacy Policy      Patents